Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PnMAPS30plus Pneumococcal Vaccine in Adults 50-64 Years
NCT07428759Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK5459248 in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Number of Participants with Solicited Administration Site Adverse Events at 7 days, Number of Participants with Solicited Systemic Adverse Events at 7 days and 5 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
GSK5459248
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07428759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428759.